Lonza has completed the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of $4.6 billion.   Albert M. Baehny, chairman, Lonza commented, “Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new structure and identity and refining our focus as a pure-play partner to the healthcare industry. As the divestment of the Specialty Ingredients business ...